New clinical and experimental approaches for studying tumor dormancy: Does tumor dormancy offer a therapeutic target?

APMIS

Volumn 116, Issue 7-8, 2008, Pages 552-568

  Goss, Paul ^a   Allan, Alison L ^b   Rodenhiser, David I ^b,c   Foster, Paula J ^b,d   Chambers, Ann F ^b,e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c CHILDREN S HEALTH RESEARCH INSTITUTE   (Canada)

^d ROBARTS RESEARCH INSTITUTE   (Canada)

^e LONDON REGIONAL CANCER PROGRAM   (Canada)

Author keywords

Cancer stem cells; Clinical trials; Epigenetics; Magnetic resonance imaging; Tumor dormancy

Indexed keywords

LAPATINIB; LETROZOLE; TAMOXIFEN;

ANTIANGIOGENIC THERAPY; BREAST CANCER; CANCER CELL; CANCER RECURRENCE; CANCER STEM CELL; CLINICAL TRIAL; DORMANCY; HUMAN; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT;

EID: 52049084581     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2008.01059.x     Document Type: Review

References (140)

1. Carlson RW, Brown E, Burstein HJ, Gradishar WJ, Hudis CA, Loprinzi C, et al. NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. J Natl Compr Canc Netw 2006 4 (Suppl 1 S1 26.
2. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996 14 : 2197 205.
3. Early Breast Cancer Trialists' Collaborative Group EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005 365 : 1687 717.
4. Norton L. Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy. Oncologist 2005 10 : 370 81.
5. Chang JC, Hilsenback SG. Prognostic and predictive markers. In: Harris J, Lippmann M, Osborne CK. Diseases of the Breast. 3rd ed. Lippincott : Williams and Wilkins, 2004 675 96.
6. Hortobagyi GN, Kau SW, Buzdar AU, Theriault RL, Booser DJ, Gwyn K, et al. What is the prognosis of patients with operable breast cancer five years after diagnosis? Abstract 585. Proceedings of the American Society of Clinical Oncology 2004 23.
7. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006 24 : 3726 34.
8. Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004 5 : 607 16.
9. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002 347 : 1999 2009.
10. Mansi JL, Gogas H, Bliss JM, Gazet JC, Berger U, Coombes RC. Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study. Lancet 1999 354 : 197 202.
11. Mansi JL, Easton D, Berger U, Gazet JC, Ford HT, Dearnaley D, et al. Bone marrow micrometastases in primary breast cancer: prognostic significance after 6 years' follow-up. Eur J Cancer 1991 27 : 1552 5.
12. Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, et al. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 2004 10 : 8152 62.
13. Demicheli R, Terenziani M, Bonadonna G. Estimate of tumor growth time for breast cancer local recurrences: rapid growth after wake-up? Breast Cancer Res Treat 1998 51 : 133 7.
14. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005 353 : 793 802.
15. Braun S, Vogl FD, Schneitter A, Egle D, Auer D, Lang M, et al. Disseminated tumor cells: are they ready for clinical use? Breast 2007 16 (Suppl 2 51 4.
16. Ragaz J, Jackson SM, Le N, Plenderleith IH, Spinelli JJ, Basco VE, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 1997 337 : 956 62.
17. Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997 337 : 949 55.
18. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005 97 : 1262 71.
19. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003 349 : 1793 802.
20. Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001 93 : 684 90.
21. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996 88 : 1529 42.
22. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. J Clin Oncol 2007 25 : 2006 11.
23. Goss PE. Letrozole in the extended adjuvant setting: MA.17. Breast Cancer Res Treat 2007 105 (Suppl 1 45 53.
24. Moy B, Goss PE. TEACH: Tykerb evaluation after chemotherapy. Clin Breast Cancer 2007 7 : 489 92.
25. Naumov GN, MacDonald IC, Chambers AF, Groom AC. Solitary cancer cells as a possible source of tumour dormancy? Semin Cancer Biol 2001 11 : 271 6.
26. Naumov GN, MacDonald IC, Weinmeister PM, Kerkvliet N, Nadkarni KV, Wilson SM, et al. Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Res 2002 62 : 2162 8.
27. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995 1 : 149 53.
28. Brackstone M, Townson JL, Chambers AF : Tumour dormancy in breast cancer: an update. Breast Cancer Res 2007 9 : 208.
29. Townson JL, Chambers AF. Dormancy of solitary metastatic cells. Cell Cycle 2006 5 : 1744 50.
30. Townson JL, Naumov GN, Chambers AF. The role of apoptosis in tumor progression and metastasis. Curr Mol Med 2003 3 : 631 42.
31. Naumov GN, Townson JL, MacDonald IC, Wilson SM, Bramwell VH, Groom AC, et al. Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res Treat 2003 82 : 199 206.
32. Marches R, Scheuermann R, Uhr J. Cancer dormancy: from mice to man. Cell Cycle 2006 5 : 1772 8.
33. Alix-Panabieres C, Muller V, Pantel K. Current status in human breast cancer micrometastasis. Curr Opin Oncol 2007 19 : 558 63.
34. Pantel K, Alix-Panabieres C. The clinical significance of circulating tumor cells. Nat Clin Pract Oncol 2007 4 : 62 3.
35. Jenkins DE, Hornig YS, Oei Y, Dusich J, Purchio T. Bioluminescent human breast cancer cell lines that permit rapid and sensitive in vivo detection of mammary tumors and multiple metastases in immune deficient mice. Breast Cancer Res 2005 7 : R444 54.
36. Chambers AF, MacDonald IC, Schmidt EE, Koop S, Morris VL, Khokha R, et al. Steps in tumor metastasis: new concepts from intravital videomicroscopy. Cancer Metastasis Rev 1995 14 : 279 301.
37. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002 2 : 563 72.
38. Kennel SJ, Davis IA, Branning J, Pan H, Kabalka GW, Paulus MJ. High resolution computed tomography and MRI for monitoring lung tumor growth in mice undergoing radioimmunotherapy: correlation with histology. Med Phys 2000 27 : 1101 7.
39. Graham KC, Wirtzfeld LA, MacKenzie LT, Postenka CO, Groom AC, MacDonald IC, et al. Three-dimensional high-frequency ultrasound imaging for longitudinal evaluation of liver metastases in preclinical models. Cancer Res 2005 65 : 5231 7.
40. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2002 2 : 683 93.
41. Blankenberg FG, Katsikis PD, Tait JF, Davis RE, Naumovski L, Ohtsuki K, et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci U S A 1998 95 : 6349 54.
42. Weissleder R. Scaling down imaging: molecular mapping of cancer in mice. Nat Rev Cancer 2002 2 : 11 8.
43. Arbab AS, Liu W, Frank JA. Cellular magnetic resonance imaging: current status and future prospects. Expert Rev Med Devices 2006 3 : 427 39.
44. Weissleder R, Mahmood U. Molecular imaging. Radiology 2001 219 : 316 33.
45. Modo M, Hoehn M, Bulte JW. Cellular MR imaging. Mol Imaging 2005 4 : 143 64.
46. Bulte JW, Kraitchman DL. Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed 2004 17 : 484 99.
47. Weissleder R, Cheng HC, Bogdanova A, Bogdanov A Jr. Magnetically labeled cells can be detected by MR imaging. J Magn Reson Imaging 1997 7 : 258 63.
48. Wu YL, Ye Q, Foley LM, Hitchens TK, Sato K, Williams JB, et al. In situ labeling of immune cells with iron oxide particles: an approach to detect organ rejection by cellular MRI. Proc Natl Acad Sci USA 2006 103 : 1852 7.
49. Slotkin JR, Cahill KS, Tharin SA, Shapiro EM. Cellular magnetic resonance imaging: nanometer and micrometer size particles for noninvasive cell localization. Neurotherapeutics 2007 4 : 428 33.
50. Giesel FL, Stroick M, Griebe M, Troster H, von der Lieth CW, Requardt M, et al. Gadofluorine m uptake in stem cells as a new magnetic resonance imaging tracking method: an in vitro and in vivo study. Invest Radiol 2006 41 : 868 73.
51. Strijkers GJ, Mulder WJ, van Tilborg GA, Nicolay K. MRI contrast agents: current status and future perspectives. Anticancer Agents Med Chem 2007 7 : 291 305.
52. Wang YX, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol 2001 11 : 2319 31.
53. Moore A, Marecos E, Bogdanov A Jr., Weissleder R. Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model. Radiology 2000 214 : 568 74.
54. Bulte JW, Duncan ID, Frank JA. In vivo magnetic resonance tracking of magnetically labeled cells after transplantation. J Cereb Blood Flow Metab 2002 22 : 899 907.
55. Evgenov NV, Medarova Z, Dai G, Bonner-Weir S, Moore A. In vivo imaging of islet transplantation. Nat Med 2006 12 : 144 8.
56. Oweida AJ, Dunn EA, Foster PJ. Cellular imaging at 1.5 T: detecting cells in neuroinflammation using active labeling with superparamagnetic iron oxide. Mol Imaging 2004 3 : 85 95.
57. Dunn EA, Weaver LC, Dekaban GA, Foster PJ. Cellular imaging of inflammation after experimental spinal cord injury. Mol Imaging 2005 4 : 53 62.
58. Tai JH, Foster P, Rosales A, Feng B, Hasilo C, Martinez V, et al. Imaging islets labeled with magnetic nanoparticles at 1.5 Tesla. Diabetes 2006 55 : 2931 8.
59. Foster PJ, Dunn EA, Karl KE, Snir JA, Nycz CM, Harvey AJ, et al. Cellular MRI: in vivo imaging of melanoma cells in lymph nodes of mice. Manuscript submitted.
60. Josephson L, Lewis J, Jacobs P, Hahn PF, Stark DD. The effects of iron oxides on proton relaxivity. Magn Reson Imaging 1988 6 : 647 53.
61. Hinds KA, Hill JM, Shapiro EM, Laukkanen MO, Silva AC, Combs CA, et al. Highly efficient endosomal labeling of progenitor and stem cells with large magnetic particles allows magnetic resonance imaging of single cells. Blood 2003 102 : 867 72.
62. Neri M, Maderna C, Cavazzin C, Deidda-Vigoriti V, Politi LS, Scotti G, et al. Efficient in vitro labeling of human neural precursor cells with superparamagnetic iron oxide particles: relevance for in vivo cell tracking. Stem Cells 2008 26 : 505 16.
63. Engberink RD, Blezer EL, Hoff EI, van der Pol SM, van der Toorn A, Dijkhuizen RM, et al. MRI of monocyte infiltration in an animal model of neuroinflammation using SPIO-labeled monocytes or free USPIO. J Cereb Blood Flow Metab 2008 28 : 841 51.
64. Bulte JW, Ben-Hur T, Miller BR, Mizrachi-Kol R, Einstein O, Reinhartz E, et al. MR microscopy of magnetically labeled neurospheres transplanted into the Lewis EAE rat brain. Magn Reson Med 2003 50 : 201 5.
65. de Vries IJ, Lesterhuis WJ, Barentsz JO, Verdijk P, van Krieken JH, Boerman OC, et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol 2005 23 : 1407 13.
66. Heyn C, Ronald JA, Mackenzie LT, MacDonald IC, Chambers AF, Rutt BK, et al. In vivo magnetic resonance imaging of single cells in mouse brain with optical validation. Magn Reson Med 2006 55 : 23 9.
67. Shapiro EM, Sharer K, Skrtic S, Koretsky AP. In vivo detection of single cells by MRI. Magn Reson Med 2006 55 : 242 9.
68. Heyn C, Ronald JA, Ramadan SS, Snir JA, Barry AM, MacKenzie LT, et al. In vivo MRI of cancer cell fate at the single-cell level in a mouse model of breast cancer metastasis to the brain. Magn Reson Med 2006 56 : 1001 10.
69. Arbab AS, Bashaw LA, Miller BR, Jordan EK, Lewis BK, Kalish H, et al. Characterization of biophysical and metabolic properties of cells labeled with superparamagnetic iron oxide nanoparticles and transfection agent for cellular MR imaging. Radiology 2003 229 : 838 46.
70. Shapiro EM, Skrtic S, Sharer K, Hill JM, Dunbar CE, Koretsky AP. MRI detection of single particles for cellular imaging. Proc Natl Acad Sci USA 2004 101 : 10901 6.
71. Cohen B, Dafni H, Meir G, Harmelin A, Neeman M. Ferritin as an endogenous MRI reporter for noninvasive imaging of gene expression in C6 glioma tumors. Neoplasia 2005 7 : 109 17.
72. Cohen B, Ziv K, Plaks V, Israely T, Kalchenko V, Harmelin A, et al. MRI detection of transcriptional regulation of gene expression in transgenic mice. Nat Med 2007 13 : 498 503.
73. Genove G, DeMarco U, Xu H, Goins WF, Ahrens ET. A new transgene reporter for in vivo magnetic resonance imaging. Nat Med 2005 11 : 450 4.
74. Gupta AK, Naregalkar RR, Vaidya VD, Gupta M. Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications. Nanomed 2007 2 : 23 39.
75. Sosnovik DE, Weissleder R. Emerging concepts in molecular MRI. Curr Opin Biotechnol 2007 18 : 4 10.
76. Leuschner C, Kumar CS, Hansel W, Soboyejo W, Zhou J, Hormes J. LHRH-conjugated magnetic iron oxide nanoparticles for detection of breast cancer metastases. Breast Cancer Res Treat 2006 99 : 163 76.
77. Funovics MA, Kapeller B, Hoeller C, Su HS, Kunstfeld R, Puig S, et al. MR imaging of the her2/neu and 9.2.27 tumor antigens using immunospecific contrast agents. Magn Reson Imaging 2004 22 : 843 50.
78. Sun C, Sze R, Zhang M. Folic acid-PEG conjugated superparamagnetic nanoparticles for targeted cellular uptake and detection by MRI. J Biomed Mater Res A 2006 78 : 550 7.
79. Zhang C, Jugold M, Woenne EC, Lammers T, Morgenstern B, Mueller MM, et al. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res 2007 67 : 1555 62.
80. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007 7 : 834 46.
81. Allan AL, Vantyghem SA, Tuck AB, Chambers AF. Tumor dormancy and cancer stem cells: implications for the biology and treatment of breast cancer metastasis. Breast Dis 2006 26 : 87 98.
82. Rodenhiser D, Mann M. Epigenetics and human disease: translating basic biology into clinical applications. CMAJ 2006 174 : 341 8.
83. Bird A. Perceptions of epigenetics. Nature 2007 447 : 396 8.
84. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007 8 : 286 98.
85. Bernstein BE, Meissner A, Lander ES. The mammalian epigenome. Cell 2007 128 : 669 81.
86. Li B, Carey M, Workman JL. The role of chromatin during transcription. Cell 2007 128 : 707 19.
87. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001 61 : 3225 9.
88. Brena RM, Costello JF. Genome-epigenome interactions in cancer. Hum Mol Genet 2007 16 : R96 105.
89. Li LC. Epigenetics of prostate cancer. Front Biosci 2007 12 : 3377 97.
90. Agrawal A, Murphy RF, Agrawal DK. DNA methylation in breast and colorectal cancers. Mod Pathol 2007 20 : 711 21.
91. Wilson AS, Power BE, Molloy PL. DNA hypomethylation and human diseases. Biochim Biophys Acta 2007 1775 : 138 62.
92. Hoffmann MJ, Schulz WA. Causes and consequences of DNA hypomethylation in human cancer. Biochem Cell Biol 2005 83 : 296 321.
93. Miremadi A, Oestergaard MZ, Pharoah PD, Caldas C. Cancer genetics of epigenetic genes. Hum Mol Genet 2007 161 : R28 49.
94. Kim YI. Folate and DNA methylation: a mechanistic link between folate deficiency and colorectal cancer?!1. Cancer Epidemiol Biomarkers Prev 2004 13 : 511 9.
95. Shahrzad S, Bertrand K, Minhas K, Coomber BL. Induction of DNA hypomethylation by tumor hypoxia. Epigenetics 2007 2 : 119 25.
96. Gheorghe CP, Mohan S, Oberg KC, Longo LD. Gene expression patterns in the hypoxic murine placenta: a role in epigenesis? Reprod Sci 2007 97 : 119 24.
97. Chawla RK, Watson WH, Jones DP. Effect of hypoxia on hepatic DNA methylation and tRNA methyltransferase in rat: similarities to effects of methyl-deficient diets. J Cell Biochem 1996 61 : 72 80.
98. Avila MA, Carretero MV, Rodriguez EN, Mato JM. Regulation by hypoxia of methionine adenosyltransferase activity and gene expression in rat hepatocytes. Gastroenterology 1998 114 : 364 71.
99. Zygmunt A, Tedesco VC, Udho E, Krucher NA. Hypoxia stimulates p16 expression and association with cdk4. Exp Cell Res 2002 278 : 53 60.
100. Fraga MF, Esteller M. Epigenetics and aging: the targets and the marks. Trends Genet 2007 23 : 413 8.
101. Casillas MA Jr., Lopatina N, Andrews LG, Tollefsbol TO. Transcriptional control of the DNA methyltransferases is altered in aging and neoplastically-transformed human fibroblasts. Mol Cell Biochem 2003 252 : 33 43.
102. Pogribny IP, Tryndyak VP, Muskhelishvili L, Rusyn I, Ross SA. Methyl deficiency, alterations in global histone modifications, and carcinogenesis. J Nutr 2007 137 : 216S 22S.
103. Sadikovic B, Andrews J, Carter D, Robinson J, Rodenhiser DI. Genome-wide H3K9 histone acetylation profiles are altered in benzopyrene treated MCF7 breast cancer cells. J Biol Chem 2008 283 : 4051 60.
104. Postovit LM, Costa FF, Bischof JM, Seftor EA, Wen B, Seftor RE, et al. The commonality of plasticity underlying multipotent tumor cells and embryonic stem cells. J Cell Biochem 2007 101 : 908 17.
105. Postovit LM, Seftor EA, Seftor RE, Hendrix MJ. A three-dimensional model to study the epigenetic effects induced by the microenvironment of human embryonic stem cells. Stem Cells 2006 24 : 501 5.
106. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer 2004 4 : 448 56.
107. Cameron MD, Schmidt EE, Kerkvliet N, Nadkarni KV, Morris VL, Groom AC, et al. Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency. Cancer Res 2000 60 : 2541 6.
108. Luzzi KJ, MacDonald IC, Schmidt EE, Kerkvliet N, Morris VL, Chambers AF, et al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 1998 153 : 865 73.
109. Weiss L. Metastatic inefficiency. Adv Cancer Res 1990 54 : 159 211.
110. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007 1 : 313 23.
111. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003 100 : 3983 8.
112. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005 65 : 10946 51.
113. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007 445 : 106 10.
114. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature 2004 432 : 396 401.
115. Croker AK, Allan AL. Cancer stem cells: implications for the progression and treatment of metastatic disease. J Cell Mol Med 2008 12 : 374 90.
116. Li F, Tiede B, Massague J, Kang Y. Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res 2007 17 : 3 14.
117. Phillips TM, McBride WH, Pajonk F. The response of CD24-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006 98 : 1777 85.
118. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005 65 : 5506 11.
119. Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, et al. CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 2006 8 : R59.
120. Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 2005 11 : 1154 9.
121. Balic M, Lin H, Young L, Hawes D, Giuliano A, McNamara G, et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 2006 12 : 5615 21.
122. Liu R, Wang X, Chen GY, Dalerba P, Gurney A, Hoey T, et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 2007 356 : 217 26.
123. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, et al. Cancer stem cells - perspectives on current status and future directions: AACR Workshop on Cancer Stem Cells. Cancer Res 2006 66 : 9339 44.
124. Al-Hajj M, Clarke MF. Self-renewal and solid tumor stem cells. Oncogene 2004 23 : 7274 82.
125. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001 414 : 105 11.
126. Hendrix MJ, Seftor EA, Seftor RE, Kasemeier-Kulesa J, Kulesa PM, Postovit LM. Reprogramming metastatic tumour cells with embryonic microenvironments. Nat Rev Cancer 2007 7 : 246 55.
127. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005 438 : 820 7.
128. Liu S, Dontu G, Mantle ID, Patel S, Ahn NS, Jackson KW, et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 2006 66 : 6063 71.
129. Thayer SP, di Magliano MP, Heiser PW, Nielsen CM, Roberts DJ, Lauwers GY, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003 425 : 851 6.
130. Wang S, Yang D, Lippman ME. Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists. Semin Oncol 2003 30 : 133 42.
131. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005 5 : 275 84.
132. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 2003 3 : 895 902.
133. Cairns J. Somatic stem cells and the kinetics of mutagenesis and carcinogenesis. Proc Natl Acad Sci USA 2002 99 : 10567 70.
134. Shinin V, Gayraud-Morel B, Gomes D, Tajbakhsh S. Asymmetric division and cosegregation of template DNA strands in adult muscle satellite cells. Nat Cell Biol 2006 8 : 677 87.
135. Li L, Neaves WB. Normal stem cells and cancer stem cells: the niche matters. Cancer Res 2006 66 : 4553 7.
136. Spradling A, Drummond-Barbosa D, Kai T. Stem cells find their niche. Nature 2001 414 : 98 104.
137. Tumbar T, Guasch G, Greco V, Blanpain C, Lowry WE, Rendl M, et al. Defining the epithelial stem cell niche in skin. Science 2004 303 : 359 63.
138. Zhang J, Niu C, Ye L, Huang H, He X, Tong WG, et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003 425 : 836 41.
139. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007 449 : 557 63.
140. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea - a paradigm shift. Cancer Res 2006 66 : 1883 90 discussion 95-6.